New program aims to break the Pain-Depression cycle in older women
NCT ID NCT05619510
First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 3 times
Summary
This study tested a program called PRIME for older women with chronic pain and depression who also have physical disabilities. Nine women took part in nurse-led goal-setting visits and group therapy sessions focused on acceptance and commitment. The goal was to see if this combined approach could reduce pain and improve mood without medication.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PRIME Intervention (behavioral: nurse goal-setting visits and Acceptance Commitment Therapy group sessions)
- What this could lead to
- If it works, this could offer a non-drug way to help older women with disabilities manage both chronic pain and depression together.
- What could go wrong
- This was a very small pilot study with only 9 participants, so results may not apply to everyone. The program is time-intensive and may not work for all.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEPRESSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Johns Hopkins School of Nursing
Baltimore, Maryland, 21213, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Your voice may hold clues to depression – a new device listens in
- Can a virtual meadow or a Mind's eye stream calm hospital anxiety?
- Could the sound of your voice reveal depression?
- Can MRI reveal the Brain's response to deep brain stimulation?
- Can a coordinated care team ease the aftermath of intensive care?
- Could a new drug offer hope for Treatment-Resistant depression?